JP2024544060A - Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法 - Google Patents

Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法 Download PDF

Info

Publication number
JP2024544060A
JP2024544060A JP2024532219A JP2024532219A JP2024544060A JP 2024544060 A JP2024544060 A JP 2024544060A JP 2024532219 A JP2024532219 A JP 2024532219A JP 2024532219 A JP2024532219 A JP 2024532219A JP 2024544060 A JP2024544060 A JP 2024544060A
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
groups
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544060A5 (https=
Inventor
ティモシー ジェイ． センター，
レスリー エー． デーキン，
ミン チェン，
スティーブン ディー． ストーン，
エレナ ドルギフ，
ジェシカ エイチ． オルセン，
ハオシュアン ワン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2024544060A publication Critical patent/JP2024544060A/ja
Publication of JP2024544060A5 publication Critical patent/JP2024544060A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0834—Compounds having one or more O-Si linkage
    • C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024532219A 2021-11-30 2022-11-29 Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法 Pending JP2024544060A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284195P 2021-11-30 2021-11-30
US63/284,195 2021-11-30
PCT/US2022/051274 WO2023101981A1 (en) 2021-11-30 2022-11-29 Spirocyclic inhibitors of apol1 and methods of using same

Publications (2)

Publication Number Publication Date
JP2024544060A true JP2024544060A (ja) 2024-11-27
JP2024544060A5 JP2024544060A5 (https=) 2025-10-30

Family

ID=84946826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532219A Pending JP2024544060A (ja) 2021-11-30 2022-11-29 Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法

Country Status (7)

Country Link
US (1) US20250084094A1 (https=)
EP (1) EP4440697A1 (https=)
JP (1) JP2024544060A (https=)
CN (1) CN118632850A (https=)
AU (1) AU2022401847A1 (https=)
CA (1) CA3240523A1 (https=)
WO (1) WO2023101981A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503737A (ja) * 2022-01-18 2025-02-04 メイズ セラピューティクス， インコーポレイテッド Ａｐｏｌ１阻害剤及び使用方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CA3185604A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618746B2 (en) * 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021154997A1 (en) * 2020-01-29 2021-08-05 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
JP2023524563A (ja) * 2020-05-07 2023-06-12 ラムバム メド－テック リミテッド Ａｐｏｌ１－関連疾患の治療に使用するための組成物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025503737A (ja) * 2022-01-18 2025-02-04 メイズ セラピューティクス， インコーポレイテッド Ａｐｏｌ１阻害剤及び使用方法

Also Published As

Publication number Publication date
CN118632850A (zh) 2024-09-10
US20250084094A1 (en) 2025-03-13
AU2022401847A1 (en) 2024-06-06
WO2023101981A1 (en) 2023-06-08
EP4440697A1 (en) 2024-10-09
CA3240523A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
JP2024544060A (ja) Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法
JP2024543934A (ja) Ａｐｏｌ１の阻害剤としての４－フェニル－２－（１ｈ－１，２，３－トリアゾール－４－イル）ピペリジン－４－オール誘導体、およびそれを使用する方法
JP2025505200A (ja) Ａｐｏｌ１の阻害剤としての２－メチル－４－フェニルピペリジン－４－オール誘導体、及びそれを使用する方法
JP2025505644A (ja) Ａｐｏｌ１の阻害剤としての４’，５’－ジヒドロスピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、及びそれを使用する方法
CN116528864A (zh) 杂芳基甲酰胺化合物
CA2895426A1 (en) Bet-protein-inhibiting dihydroquinoxalinones
JP2010521528A (ja) Ｃｎｓ活性化合物としてのインドリジン及びそのアザ類似誘導体
WO2015087151A1 (en) Novel azaindole derivatives as selective histone deacetylase (hdac) inhibitors and pharmaceutical compositions comprising the same
EP3271361B1 (en) Tricyclic heterocyclic compounds useful as inhibitors of tnf
US20100120730A1 (en) 6-benzyl-2,3,4,7-tetrahydro-indolo [2,3-c] quinoline compounds useful as pde5 inhibitors
CA3179333A1 (en) Modulators of alpha-1 antitrypsin
CA2954218C (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
KR20170129810A (ko) 치환된 트리시클릭 헤테로시클릭 화합물
KR20170042711A (ko) 치환된 비시클릭 화합물
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
CA3029086A1 (en) Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof
JP2022528919A (ja) Ｍａｌｔ１阻害剤としての尿素誘導体
TW201726651A (zh) ２，３，４，５－四氫吡啶－６－胺衍生物
TWI768781B (zh) 轉化生長因子－β受體抑制劑
TWI914378B (zh) 作為ａｌｋ５抑制劑之嗒𠯤基胺基衍生物
US5109013A (en) 2-(2-substituted aminoethyl)-1,4-dialkyl-3,4-dihydro-1H-1,3,5]triazepino[3,2-a]benzimidazol-5(2H)-ones as muscle relaxants
OA21973A (en) 4-Phenyl-2-(1H-1,2,3-Triazol-4-YL) Piperidin-4-OL derivatives as inhibitors Of APOL1 and methods of using same.
EA053250B1 (ru) Производные 4-фенил-2-(1h-1,2,3-триазол-4-ил)пиперидин-4-ола в качестве ингибиторов apol1 и способы их применения
CN118574809A (zh) 作为apol1抑制剂的4-苯基-2-(1h-1,2,3-三唑-4-基)哌啶-4-醇衍生物和其使用方法
WO2025032440A1 (en) Klf2 inducing compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251022